Abstract:Rosacea is a chronic skin inflammatory disease with a global prevalence ranging from 1% to 20%. It is characterized by facial erythema, telangiectasia, papules, pustules, and ocular manifestations. Its pathogenesis involves a complex interplay of genetic, environmental, immune, microbial, and neurovascular factors. Recent studies have advanced our understanding of its molecular basis, focusing on toll-like receptor (TLR) 2 pathways, LL37 expression, mammalian target of rapamycin (mTOR) activation, interleukin (IL)-17 signaling, transient receptor potential vanilloid (TRPV) functions, and the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathways. LL37-associated signaling pathways, particularly involving TLR2 and mTORC1, are critical in the pathogenesis of rosacea. LL37 interacts with signaling molecules such as extracellular signal-regulated kinases 1 and 2 (ERK1/2), nuclear factor kappa B (NF-κB), inflammasomes, C-X-C motif chemokine ligand 8 (CXCL8), mas-related G-protein-coupled receptor X2 (MRGPRX2)-TRPV4, and vascular endothelial growth factor (VEGF). This interaction activates macrophages, neutrophils, mast cells, and vascular endothelial cells, leading to cytokine release including tumor necrosis factor-alpha (TNF-α), IL-6, IL-1β, C motif chemokine ligand (CCL) 5, CXCL9, and CXCL10. These processes contribute to immune response modulation, inflammation, and angiogenesis in rosacea pathophysiology. The IL-17 signaling pathway also plays a crucial role in rosacea, affecting angiogenesis and the production of inflammatory cytokines. In addition, recent insights into the JAK/STAT pathways have revealed their integral role in inflammatory and angiogenic mechanisms associated with rosacea. Rosacea treatment currently focuses on symptom management, with emerging insights into these molecular pathways providing more targeted and effective therapies. Biological agents targeting specific cytokines, IL-17 inhibitors, JAK inhibitors, and VEGF antagonists are promising for future rosacea therapy, aiming for enhanced efficacy and fewer side effects. This review provides a comprehensive overview of the current knowledge regarding signaling pathways in rosacea and potential targeted therapeutic strategies.

TLR7 Promotes Skin Inflammation Via Activating NFκB-mTORC1 Axis in Rosacea.

Signaling pathways and targeted therapy for rosacea

Aging-Conferred SIRT7 Decline Inhibits Rosacea-Like Skin Inflammation by Modulating Toll-Like Receptor 2‒NF-κB Signaling

A positive feedback loop between mTORC1 and cathelicidin promotes skin inflammation in rosacea

TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes

Targeting Aquaporin-3 Attenuates Skin Inflammation in Rosacea.

Mtorc1-Mediated Angiogenesis is Required for the Development of Rosacea

Aquaporin-3 Upregulation Promotes Rosacea-Like Inflammation by Inducing NF-kB Activation in Keratinocytes and Th17 Cell Differentiation

Activation of aryl hydrocarbon receptor ameliorates rosacea-like eruptions in mice and suppresses the TLR signaling pathway in LL-37-induced HaCaT cells

Tranilast alleviates skin inflammation and fibrosis in rosacea-like mice induced by long-term exposure to LL-37

LncRNA NEAT1 targets miR-125/ADAM9 mediated NF-κB pathway in inflammatory response of rosacea

Keratinocyte-Immune Cell Crosstalk in a STAT1-Mediated Pathway: Novel Insights Into Rosacea Pathogenesis

Targeting the STAT3/IL-36G Signaling Pathway Can Be a Promising Approach to Treat Rosacea

Dietary supplementation of n-3 PUFAs ameliorates LL37-induced rosacea-like skin inflammation via inhibition of TLR2/MyD88/NF-κB pathway

Single-cell transcriptomics reveals aberrant skin-resident cell populations and identifies fibroblasts as a determinant in rosacea

OPN Promotes Pro-Inflammatory Cytokine Expression Via ERK/JNK Pathway and M1 Macrophage Polarization in Rosacea

Identification of novel candidate genes in rosacea by bioinformatic methods

Tranexamic acid ameliorates rosacea symptoms through regulating immune response and angiogenesis

S100A9 exacerbates the inflammation in rosacea via TLR4/MyD88/NF-κB signaling pathway

High-sensitive sensory neurons exacerbate rosacea-like dermatitis in mice by activating γδ T cells directly

The treatment of Tofacitinib for rosacea through the inhibition of the JAK/STAT signaling pathway